[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346167-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-346167-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","targeting-usp22-reprograms-the-tumor-microenvironment-and-sensitizes-krasp53-driven-lung-cancer-to-anti-pd-1-immunotherapy-research-paper","Targeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy - Research Paper","","Ubiquitin-specific peptidase 22 (USP22) is a deubiquitinase linked to cancer recurrence, therapy resistance, and poor prognosis, yet its function in KRAS/p53-driven lung cancer and response to immune checkpoint inhibitors remains unclear. This study generated a conditional Usp22 knockout in KRASG12D; p53−/− mice and evaluated tumor progression by micro-CT and tumor microenvironment remodeling via multiplex immunofluorescence, RNA sequencing, and spatial transcriptomics. USP22 loss reduced tumor growth, extended survival, and promoted differentiation while decreasing immunosuppressive CD206+ M2 macrophages, MDSCs, TGF-β1, and angiogenesis, alongside increasing functional CD8+ T cells. Mechanistically, USP22 regulated gene expression and protein stability, lowering c-Myc, PD-L1, TGF-β1, and SPARC, and USP22 targeting enhanced anti-PD-1/PD-L1 efficacy in orthotopic and subcutaneous models.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-usp22-reprograms-the-tumor-microenvironment-and-sensitizes-krasp53-driven-lung-cancer-to-anti-pd-1-immunotherapy-research-paper/346167/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-usp22-reprograms-the-tumor-microenvironment-and-sensitizes-krasp53-driven-lung-cancer-to-anti-pd-1-immunotherapy-research-paper/346167.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What role does USP22 play in KRAS/p53-driven lung cancer?","Question",{"text":63,"@type":64},"USP22 promotes progression and immune evasion in KRAS/p53-driven lung cancer. It is highly expressed in early-stage tumors and correlates with proliferation marker Ki67.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was USP22 function tested in the study?",{"text":68,"@type":64},"The authors created a conditional Usp22 knockout (Usp22-KO) in the KRASG12D; p53−/− mouse model. Tumor growth and tumor microenvironment changes were assessed using micro-CT, multiplex immunofluorescence, RNA sequencing, and spatial transcriptomics.",{"name":70,"@type":61,"acceptedAnswer":71},"What immune microenvironment changes occur after USP22 loss?",{"text":72,"@type":64},"USP22 deletion suppressed tumor growth and prolonged survival while reducing CD206+ M2 macrophages, MDSCs, TGF-β1, and angiogenesis. It also increased functional CD8+ T cells.",{"name":74,"@type":61,"acceptedAnswer":75},"Does targeting USP22 affect responses to immune checkpoint therapy?",{"text":76,"@type":64},"Yes. Usp22 loss enhanced the efficacy of anti-PD-L1 and anti-PD-1 therapies in orthotopic and subcutaneous KRAS/p53-driven lung cancer models.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},346167,1790185311,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Theranostics 2026, Vol. 16, Issue 15 8708  \nIvyspring  \nInternational Publisher  \nTheranostics  \n2026; 16(15): 8708-8732. doi: 10.7150/thno.125898  \nResearch Paper  \nTargeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy  \nKeqiang Zhang1􀀍, Ching Ouyang2, Jonathan Castillo3, Jinhui Wang2, Walter Tsark4, Yuanyuan Gao1, Wendong Li1, Minxiao Yang3, Aimin Li5, Britney Oeung6, Colt Egelston6, Jun Wu7, Mahima Raul1, Leonidas Arvanitis8, Crystal Marconett3, Dan J Raz1􀀍  \n1. Division of Thoracic Surgery, City of Hope National Medical Center, Duarte, California, USA.  \n2. Integrative Genomics Core, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.  \n3. Department of Integrative Translational Sciences, City of Hope National Medical Center, Duarte, CA, USA.  \n4. Transgenic/Knockout Program, City of Hope National Medical Center, Duarte, CA, USA.  \n5. Pathology Core of Shared Resources, City of Hope National Medical Center, Duarte, CA, USA.  \n6. Immuno-Oncology Facility, Department of Immune-Oncology, City of Hope National Medical Center, Duarte, CA, USA.  \n7. Division of Comparative Medicine, City of Hope National Medical Center, Duarte, CA, USA.  \n8. Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA.  \n􀀍 Corresponding authors: Dan J. Raz, M.D, Professor, City of Hope National Medical Center, 1500E Duarte Road, Duarte, CA 91010. Phone: 626-278-7721; E[mail: draz@coh.org. Keqiang Zhang](mail: draz@coh.org. Keqiang Zhang), Ph.D, Associate Research Professor. Phone: 626-218-4178; [E-mail: kzhang@coh.org](E-mail: kzhang@coh.org).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.09.26; Accepted: 2026.07. 31; Published: 2026.08.12  \nAbstract  \nRationale: Ubiquitin-specific peptidase 22 (USP22), a deubiquitinase and component of the “Death-from-Cancer” 11-gene signature, is overexpressed in multiple malignancies and linked to recurrence, therapy resistance, and poor prognosis. Its role in KRAS/p53-driven lung cancer and the response to immune checkpoint inhibitors (ICIs) remains poorly defined. Here, we investigated USP22 as a potential therapeutic target in KRAS/p53-driven lung cancer.  \nMethods: A conditional Usp22 knockout (Usp22-KO) was generated in the KRASG12D; p53−/ − (KP) mouse model. Cancer progression was monitored by micro-computed tomography (micro-CT). Multiplex immunofluorescence (mIF), RNA sequencing, and spatial transcriptomics profiled cancer and tumor microenvironment (TME) changes. Responses to anti-PD-1/PD-L1 therapies were compared between KP and Usp22-KO KP (KPU-) lung cancers.  \nResults: USP22 was highly expressed in early-stage KRAS/p53-driven mouse lung cancers and strongly correlated with proliferation marker Ki67. Usp22 deletion suppressed cancer growth, prolonged survival, and promoted cancer differentiation. Spatial transcriptomics and mIF revealed reduced CD206+ M2 macrophages, myeloid-derived suppressor cells (MDSCs), TGF-β1, and angiogenesis, along with increased functional CD8+ T cells. Mechanistically, USP22 regulated gene expression and protein stability, reducing c-Myc, PD-L1, TGF-β1, and SPARC upon Usp22 loss. Compared with KP cancer, KPU-and SPARC-knockdown KP cancers showed reduced macrophage chemotaxis and impaired basal- and TGF-β1-induced M2 polarization of RAW264.7 cells, suggesting that TGF-β1 and SPARC downregulation partially contributes to decreased M2 macrophage infiltration in KPUcancers. Notably, Usp22 loss enhanced the efficacy of anti-PD-L1 and anti-PD-1 therapies in orthotopic and subcutaneous KP lung cancer models, respectively. USP22 and SPARC expression were also strongly correlated in human lung cancers. Conclu","cbCaidlEyDP6G4Cl","https://ap.wps.com/l/cbCaidlEyDP6G4Cl","pdf",45061507,25,"English","# Abstract\n## Rationale\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What role does USP22 play in KRAS/p53-driven lung cancer?\",\"answer\":\"USP22 promotes progression and immune evasion in KRAS/p53-driven lung cancer. It is highly expressed in early-stage tumors and correlates with proliferation marker Ki67.\"},{\"question\":\"How was USP22 function tested in the study?\",\"answer\":\"The authors created a conditional Usp22 knockout (Usp22-KO) in the KRASG12D; p53−/− mouse model. Tumor growth and tumor microenvironment changes were assessed using micro-CT, multiplex immunofluorescence, RNA sequencing, and spatial transcriptomics.\"},{\"question\":\"What immune microenvironment changes occur after USP22 loss?\",\"answer\":\"USP22 deletion suppressed tumor growth and prolonged survival while reducing CD206+ M2 macrophages, MDSCs, TGF-β1, and angiogenesis. It also increased functional CD8+ T cells.\"},{\"question\":\"Does targeting USP22 affect responses to immune checkpoint therapy?\",\"answer\":\"Yes. Usp22 loss enhanced the efficacy of anti-PD-L1 and anti-PD-1 therapies in orthotopic and subcutaneous KRAS/p53-driven lung cancer models.\"}]","Targeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy - Research Paper | PDF",1790060367,63,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa861d43cd5087735bff09bfd97f1242.webp",983,1272,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6276c4acf55eb223f45adb694cda98cf.webp",982,1270,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db3b7bb1e9d82b07d96625b0884019c2.webp",981,1269,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38b8de849926bf4d91ce78326cd077a9.webp",980,1268]